Development of Robust T Cell Manufacturing Protocols in Bioreactors Using cGMP-Compliant Ancillary Reagents

This poster presents development of scalable T-cell manufacturing protocols using cGMP-compliant activation and expansion reagents across multiple bioreactor platforms, including PBS-MINI MagDrive bioreactors. Human T cells were activated using CD3/CD28/CD2 stimulation and expanded in serum-free culture conditions with performance assessed through viability, expansion, phenotype, cytokine production, granzyme B expression, and cytotoxic activity. The PBS-MINI platform generated high fold expansion and maintained strong cell viability through a staged scale-up process. Expanded cells exhibited desirable central memory phenotypes and low expression of exhaustion markers while retaining functional activity as measured by cytokine secretion and tumor-cell killing assays. Comparisons with G-Rex and Xuri systems demonstrated that optimized protocols can support robust and reproducible T-cell manufacturing, generating clinically relevant cell yields and functional products suitable for cell therapy development and scale-up.